This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic test to predict your psychedelic-assisted therapy experience, and a potential first treatment for a debilitating form of schizophrenia.
The Heroic Dose conference will explore the use of psychedelic therapies to treat post-traumatic stress disorder, substance abuse, and suicide among military veterans and first responders.
Colorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety and depression.
Psilocybin is showing relief as treatment for cluster headaches — a painful condition that affects more than 300,000 Americans a year.
With 2 cities in the Golden State already decriminalizing psychedelics, could the rest of California be next?
Hawaii’s Senate unanimously voted to establish a working group to ensure the safety, accessibility, and affordability of psilocybin.
Potential optimal MDMA dosages for therapeutic benefit and reduced adverse events were investigated in a new study published in the latest edition of the Journal of Psychopharmacology.
New research looks at the benefits of microdosing psychedelics on wellness compared with regular yoga practice.
Following Somerville and Cambridge, Northampton, Massachusetts, is the latest city to decriminalize certain psychedelics.
This week in psychedelic business news: cannabis dives in, ketamine delivery, and psilocybin for autism anxiety.
